Segall Bryant & Hamill LLC bought a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 14,585 shares of the company's stock, valued at approximately $649,000.
Several other institutional investors also recently added to or reduced their stakes in OMCL. Smartleaf Asset Management LLC boosted its position in shares of Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after acquiring an additional 273 shares during the period. Van ECK Associates Corp boosted its holdings in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after purchasing an additional 315 shares during the period. First Horizon Advisors Inc. grew its position in Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after purchasing an additional 355 shares during the last quarter. KBC Group NV increased its holdings in shares of Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company's stock worth $92,000 after purchasing an additional 778 shares during the period. Finally, AlphaQuest LLC raised its position in shares of Omnicell by 307.8% during the fourth quarter. AlphaQuest LLC now owns 3,576 shares of the company's stock valued at $159,000 after buying an additional 2,699 shares during the last quarter. 97.70% of the stock is owned by institutional investors.
Omnicell Price Performance
Shares of Omnicell stock traded down $0.25 during midday trading on Wednesday, reaching $35.02. The company had a trading volume of 59,646 shares, compared to its average volume of 489,473. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of 129.15, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.74. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The stock has a fifty day simple moving average of $38.71 and a 200 day simple moving average of $42.46.
Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, equities research analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.
Wall Street Analyst Weigh In
OMCL has been the topic of several research reports. Wells Fargo & Company lowered their price target on Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. StockNews.com downgraded shares of Omnicell from a "buy" rating to a "hold" rating in a report on Monday, March 24th. Benchmark restated a "buy" rating and set a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. JPMorgan Chase & Co. dropped their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, March 20th. Finally, Bank of America dropped their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a report on Monday, January 6th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $51.00.
Read Our Latest Research Report on OMCL
About Omnicell
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Featured Articles
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
